Vasodilatory shock in the ICU and the role of angiotensin II

Current Opinion in Critical Care

Volumn 24, Issue 4, 2018, Pages 277-285

  Wakefield, Brett J ^a   Sacha, Gretchen L ^b   Khanna, Ashish K ^a,b  

^a Anesthesiology Institute   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

angiotensin II; catecholamines; septic shock; vasodilatory shock; vasopressors

Indexed keywords

ANGIOTENSIN II; HYPERTENSIVE FACTOR; VASOACTIVE AGENT; VASOCONSTRICTOR AGENT;

BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTENSIVE CARE UNIT; MORTALITY RATE; REVIEW; SEPTIC SHOCK; SHOCK; TREATMENT RESPONSE; VASOCONSTRICTION; VASODILATATION; VASODILATORY SHOCK; BLOOD PRESSURE MEASUREMENT; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; TREATMENT OUTCOME;

ANGIOTENSIN II; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; HUMANS; INTENSIVE CARE UNITS; MONITORING, PHYSIOLOGIC; SHOCK, SEPTIC; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 85050227788     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0000000000000517     Document Type: Review

References (53)

1. Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595.
2. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315:801-810.
3. Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA 2017; 318: 1241-1249.
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310.
5. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.
6. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017; 43:304-377.
7. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596.
8. Kumar A, Ellis P, Arabi Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. Chest 2009; 136:1237-1248.
9. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327.
10. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873.
11. Sakr Y, Reinhart K, Vincent JL, et al. Does dopamine administration in shock influence outcome? Results of the sepsis occurrence in acutely ill patients (SOAP) study. Crit Care Med 2006; 34:589-597.
12. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779-789.
13. De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis. Crit Care Med 2012; 40:725-730.
14. Avni T, Lador A, Lev S, et al. Vasopressors for the treatment of septic shock: systematic review and meta-analysis. PLoS One 2015; 10:e0129305.
15. Annane D, Vignon P, Renault A, et al. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. Lancet 2007; 370:676-684.
16. Myburgh JA, Higgins A, Jovanovska A, et al. A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 2008; 34:2226-2234.
17. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008; 358:877-887.
18. Gordon AC, Mason AJ, Thirunavukkarasu N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 2016; 316:509-518.
19. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96:576-582.
20. Gordon AC, Wang N, Walley KR, et al. The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest 2012; 142:593-605.
21. 1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care 2017; 21:213.
22. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580-637.
23. Dunser MW, Ruokonen E, Pettila V, et al. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 2009; 13:R181.
24. Dargent A, Nguyen M, Fournel I, et al. Vasopressor cumulative dose requirement and risk of early death during septic shock: an analysis from the Episs Cohort. Shock 2018; 49:625-630.
25. Andreis DT, Singer M. Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. Intensive Care Med 2016; 42:1387-1397.
26. Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 2017; 377:419-430.
27. Lamontagne F, Meade MO, Hebert PC, et al. Higher versus lower blood pressure targets for vasopressor therapy in shock: a multicentre pilot randomized controlled trial. Intensive Care Med 2016; 42:542-550.
28. Asfar P, Meziani F, Hamel JF, et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med 2014; 370:1583-1593.
29. Bourgoin A, Leone M, Delmas A, et al. Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Crit Care Med 2005; 33:780-786.
30. Khanna A, Mao G, Liu L, et al. 177: Hypotension increases acute kidney injury, myocardial injury and mortality in surgical critical care. Crit Care Med 2018; 46:71.
31. Giapreza (angiotensin II) [prescribing information]. San Diego, CA, 2017.
32. Farag E, Maheshwari K, Morgan J, et al. Anupdate of the role of renin angiotensin in cardiovascular homeostasis. Anesth Analg 2015; 120:275-292.
33. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292:C82-C97.
34. Rice CL, Kohler JP, Casey L, et al. Angiotensin-converting enzyme (ACE) in sepsis. Circ Shock 1983; 11:59-63.
35. Zhang W, Chen X, Huang L, et al. Severe sepsis: low expression of the renin-angiotensin system is associated with poor prognosis. Exp Ther Med 2014; 7:1342-1348.
36. Bumpus FM, Schwarz H, Page IH. Synthesis and pharmacology of the octapeptide angiotonin. Science 1957; 125:886-887.
37. Rittel W, Iselin B, Kappeler H, et al. Synthese von hypertensin-II-peptiden. Angew Chem 1957; 11:179.
38. Chawla LS, Busse L, Brasha-Mitchell E, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care 2014; 18:534.
39. FDA. Guidance for industry special protocol assessment. 2002; 1-11.
40. Busse LW, Wang XS, Chalikonda DM, et al. Clinical experience with IV angiotensin II administration: a systematic review of safety. Crit Care Med 2017; 45:1285-1294.
41. Ames RP, Borkowski AJ, Sicinski AM, Laragh JH. Prolonged infusions of angiotensin II and norepinephrine and blood pressure, electrolyte balance, and aldosterone and cortisol secretion in normal man and in cirrhosis with ascites. J Clin Invest 1965; 44:1171-1186.
42. Cohn JN, Luria MH. Studies in clinical shock and hypotension. II. Hemodynamic effects of norepinephrine and angiotensin. J Clin Invest 1965; 44:1494-1504.
43. Struthers AD, Pai S, Seidelin PH, et al. Evidence in humans for a postsynaptic interaction between noradrenaline and angiotensin II with regard to systolic but not diastolic blood pressure. J Hypertens 1987; 5:671-676.
44. Szerlip H, Bihorac A, Chang S, et al. Effect of disease severity on survival in patients receiving angiotensin II for vasodilatory shock. Crit Care Med 2018; 46:3.
45. Busse LW, Albertson T, Gong M, et al. Outcomes in patients with acute respiratory distress syndrome receiving angiotensin II for vasodilatory shock. Crit Care 2018; 22(Suppl 1). 82(50); (abstract P125).
46. McCurdy M, Busse LW, Gong MN, et al. Association of angiotensin II dose with all-cause mortality in patients with vasodilatory shock. Crit Care 2018; 22(Suppl 1). 82(50); (abstract P124).
47. Lankadeva YR, Kosaka J, Evans RG, et al. Urinary oxygenation as a surrogate measure of medullary oxygenation during angiotensin II therapy in septic acute kidney injury. Crit Care Med 2017; 46:e41-e48.
48. Post EH, Kellum JA, Bellomo R, Vincent JL. Renal perfusion in sepsis: from macro-to microcirculation. Kidney Int 2017; 91:45-60.
49. Tumlin JA, Murugan R, Deane AM, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med 2018; 46:949-957.
50. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86:747-803.
51. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebocontrolled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30.
52. Liu H, Yu L, Yang L, Green MS. Vasoplegic syndrome: an update on perioperative considerations. J Clin Anesth 2017; 40:63-71.
53. Wunderink RG, Albertson TE, Busse LW, et al. Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin II. Intensive Care Med Exp 2017; 5(Suppl 2):358-359.